Active, not recruitingPhase 2NCT03771898
A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
Studying Metachromatic leukodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shire
- Principal Investigator
- Study DirectorShire
- Intervention
- SHP611(drug)
- Enrollment
- 36 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, United States
- Childrens Hospital Colorado, Aurora, Colorado, United States
- Rare Disease Research, LLC, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
- Mayo Clinic - PPDS, Rochester, Minnesota, United States
- New York University Langone Medical Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Hospital Universitario Austral - PIN, Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina
- UZ Antwerpen, Edegem, Belgium
- Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Stollery Children's Hospital University of Alberta, Edmonton, Alberta, Canada
- +15 more locations on ClinicalTrials.gov
Collaborators
Takeda Development Center Americas, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03771898 on ClinicalTrials.govOther trials for Metachromatic leukodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07046338Lentiviral Hematopoietic Stem Cell Gene Therapy for MLDShenzhen Geno-Immune Medical Institute
- RECRUITINGNANCT03725670Direct Lentiviral Injection Gene Therapy for MLDShenzhen Geno-Immune Medical Institute
- ACTIVE NOT RECRUITINGPHASE3NCT04283227OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)Orchard Therapeutics
- RECRUITINGNCT04925349Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented GliaAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE2NCT02171104MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisMasonic Cancer Center, University of Minnesota
- RECRUITINGNCT03333200Longitudinal Study of Neurodegenerative DisordersUniversity of Pittsburgh